Robust Predictive Performance of MLPAS and CCMLP for Clinical Outcome and Risk Stratification in Patients with...

Area of Science:

• Oncology
• Biomarker Discovery
• Cancer Prognostics

Background:

• Colorectal cancer (CRC) lacks reliable biomarkers for prognosis in patients with negative CEA or CA19-9.
• Current methods struggle to identify high recurrence-risk CRC cases.

Purpose of the Study:

• To identify and validate novel inflammatory biomarkers for predicting prognosis in stage II-III CRC.
• To assess the role of these biomarkers in risk stratification, particularly in patients with negative CEA or CA19-9.

Main Methods:

• Utilized discovery and validation cohorts totaling 2111 radically resected stage II-III CRC patients.
• Measured preoperative peripheral monocyte, platelet, albumin (Alb), pre-albumin (pAlb), CEA, and CA19-9.
• Investigated twelve new inflammatory biomarkers for prognostic and risk-stratified roles.

Main Results:

• Several novel ratios and scores, including MLPAS, were significantly associated with RFS and OS.
• MLPAS demonstrated superior performance in predicting RFS and OS, correlating with tumor location and size.
• The CEA-CA19-9-MLPAS score (CCMLP) effectively stratified patients into low, intermediate, and high recurrence-risk groups.

Conclusions:

• MLPAS is an optimal, independent prognostic biomarker for stage II-III CRC, especially in CEA or CA19-9 negative cases.
• The CCMLP score can effectively classify high-risk CRC patients needing intensified clinical attention and management.